ReviewReports of practical oncology and radiotherapy : journal of Greatpoland Cancer Center in Poznan and Polish Society of Radiation Oncology
Dose to organ at risk and dose prescription in liver SBRT.
Review in Reports of practical oncology and radiotherapy : journal of Greatpoland Cancer Center in Poznan and Polish Society of Radiation Oncology. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 21 citations in OpenAlex.
- The identification of genes related to METTL14 inhibition in radiation-induced hepatocyte death based on bioinformatics analysis.Scientific reports · 2026Article
- Dosimetric and Delivery Assessment of Stereotactic Body Radiotherapy Using Flattened and Unflattened Beams for the Single-Isocenter Treatment of Multiple Liver Targets.Asian Pacific journal of cancer prevention : APJCP · 2026Article
- Research Progress of SBRT Combined With Immunotherapy in Locally Advanced Head and Neck Cancer.American journal of clinical oncology · 2025Review
- Diaphragm and lung dose in liver high-dose-rate interstitial brachytherapy: A dosimetry and toxicity report.Journal of contemporary brachytherapy · 2025Article
- To degas or not to degas? The effectiveness of pharmaceuticals in reducing the impact of bowel volume variations during liver SBRT treatment.Journal of medical radiation sciences · 2024Article
- Potential benefits of using radioactive ion beams for range margin reduction in carbon ion therapy.Scientific reports · 2022Article
- Characterization and Prediction of Signal Intensity Changes in Normal Liver Parenchyma on Gadoxetic Acid-enhanced MRI Scans after Liver-directed Radiation Therapy.Radiology. Imaging cancer · 2022Article
- Radiation-Induced Metabolic Shifts in the Hepatic Parenchyma: Findings fromMolecules (Basel, Switzerland) · 2021Article
- Novel Clinically Weight-Optimized Dynamic Conformal Arcs (WO-DCA) for Liver SBRT: A Comparison with Volumetric Modulated Arc Therapy (VMAT).Therapeutics and clinical risk management · 2021Article
- Slice-stacking T2-weighted MRI for fast determination of internal target volume for liver tumor.Quantitative imaging in medicine and surgery · 2021Article
- Repeated SBRT for in- and out-of-field recurrences in the liver.Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [et al] · 2019Article
- A phase I trial of Proton stereotactic body radiation therapy for liver metastases.Journal of gastrointestinal oncology · 2019Article
- Editorial.Reports of practical oncology and radiotherapy : journal of Greatpoland Cancer Center in Poznan and Polish Society of Radiation OncologyArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Stereotactic body radiation therapy (SBRT) is delivered in a curative intent to many primary and secondary tumors. Concerning liver metastasis, SBRT can be safely delivered using one to five fractions. An excellent local control is obtained with doses from 20 to 60 Gy. For primary hepatic tumors, results are also good, but the risk of hepatic toxicity related to liver pre-existent pathology must be taken into account. Radiation induced liver disease (RILD) is not frequent in its classical presentation, but modifications of liver enzymes are often observed. Other toxicities of SBRT on the duodenum, small bowel and biliary tract are also described. With respect to contraindications and dose limitations on surrounding structures, SBRT is well tolerated and takes place among curative treatment of liver tumors, as surgery, radiofrequency and embolization.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.